Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature | Zendy

Al Bishawi Ahmad | Zendy; Abdel Hadi Hamad | Zendy; Elmekaty Eman | Zendy; Al Samawi Musaed | Zendy; Nair Arun | Zendy; Abou Kamar Mohammed | Zendy; Al Maslamani Muna | Zendy; Abdelmajid Alaaeldin | Zendy

Open Access

Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature

Author(s) -

Al Bishawi Ahmad,

Abdel Hadi Hamad,

Elmekaty Eman,

Al Samawi Musaed,

Nair Arun,

Abou Kamar Mohammed,

Al Maslamani Muna,

Abdelmajid Alaaeldin

Publication year - 2022

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.5467

Subject(s) - medicine , covid-19 , intensive care medicine , pneumonia , kidney disease , authorization , disease , virology , infectious disease (medical specialty) , outbreak , computer security , computer science

Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research